These experimental data probably come as no surprise. But it is good to see a scientific quantifiable study (as opposd to some fly-by-night “doctor” giving a talk, posted in social media, about “his opinions.’).
24 August 2021
OCTAVE study’s initial findings reveal lowered vaccine responses in patients with impaired immune systems
Initial data from the ongoing OCTAVE (Observational Cohort Trial-T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2) study show that a significant proportion of clinically at-risk patients with certain immunocompromised or immunosuppressed conditions, mount a low, or undetectable, immune response after two doses of the same COVID-19 vaccine.
The OCTAVE study – a multi-centre, UK-wide trial, led by the University of Glasgow and co-ordinated by the University of Birmingham’s Cancer Research UK Clinical Trials Unit – is evaluating the immune responses following COVID-19 vaccination in patients with immune-mediated inflammatory diseases such as cancer, inflammatory arthritis, diseases of the kidney or liver, or patients who are having a stem cell transplant.
These first data from the study are published today as a pre-print on the Lancet pre-print site https://www.ssrn.com/index.cfm/en/the-lancet/
An FAQ (frequently-asked question) on the OCTAVE first results, along with accompanying images, can be found at this Dropbox link: https://www.dropbox.com/sh/nvdqazdq0jsa5wg/AADLoL0oYQW6yeAgQRn9zt4Ia?dl=0
The OCTAVE trial is one of the largest studies in the world so far into post-SARS-CoV-2 vaccination in immunocompromised patients and is funded by the Medical Research Council (MRC). OCTAVE is a collaborative research project involving groups in the Universities of Glasgow, Birmingham, Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust.
The study used a variety of state-of-the-art immune tests performed on blood samples taken before and/or after COVID-19 vaccination in about 600 people recruited across the UK. OCTAVE’s early data show that 40% of people in the patient groups studied mounted a low serological immune response after two SARS-CoV-2 vaccines.
In addition to this, the initial data show that approximately 11% of immunocompromised patients fail to generate any antibodies 4 weeks after two vaccines. Failure to generate antibodies is found at higher proportion in some specific patient sub-groups; in particular, in patients with ANCA-Associated Vasculitis who have received Rituximab treatment.
Looking in detail at patient vaccine response within each of the disease subgroups included in the study, researchers found that a significant proportion of patients studied as part of OCTAVE generate lower levels of SARS-CoV-2 antibody reactivity, when compared with healthy subjects after two SARS-CoV-2 vaccines.
The proportion of patients with lower levels of antibody reactivity was dependent on the disease cohort, with 87% of those with Rituximab treated ANCA-Associated Vasculitis, 51% of those with inflammatory arthritis, 29% of those on Haemodialysis, 42% of those on Haemodialysis receiving immunosuppressive therapy, 36% of those with Hepatic disease, 10% of those with solid cancer, 33% of those with Haematological malignancies, and 17% of patients who have undergone haemopoietic stem cell transplant responding less well than the baseline for healthy subjects.
Importantly, however, the significance of these findings in terms of what they can tell us about vaccine protection from exposure to COVID-19 is not currently known, as there is no current agreed clinical cut-off to measure COVID-19 vaccination response.
Prof Iain McInnes, lead of the OCTAVE trial, and Vice Principal and Head of the College of MVLS at the University of Glasgow, said: “The roll-out of the vaccine programme was extremely important for these vulnerable groups of patients; however, due to their underlying medical conditions and treatments, which can weaken their immune systems, we were concerned that people with these medical conditions may not receive optimal protection — so it was, and remains, extremely important to investigate this unanswered question.
“While 40% of these clinically at-risk patent groups were found to have a low or undetectable immune response after a double dose of the vaccine, we are encouraged that this figure isn’t higher. However, it is possible even partial protection may be clinically beneficial, and this is something we will closely monitor.
“There are also imminent plans in place to investigate the effects of administrating an alternate vaccine dose to the group with an undetectable or low vaccine immune response; and we hope these findings will support the role out of an immunological screening programme for vulnerable patients to identify those who will benefit from a subsequent vaccine boost.
“We would continue to encourage all people and especially those patients within these clinically at-risk groups to make sure they receive their vaccine doses, if they haven’t done so already.”
Professor Pam Kearns, Director of the University of Birmingham’s Cancer Research UK Clinical Trials Unit which is co-ordinating OCTAVE, said: “A significant number of people in the UK were advised to shield themselves, because they have conditions or long-term illnesses which place them at greater risk of severe illness and death from COVID-19.
“The rapid development of vaccines for COVID-19 has been a major step forward in the battle against this global pandemic, and the most clinically-at-risk people were among the first in the UK to be offered one. However, while we know COVID-19 vaccines are highly effective in healthy individuals, questions have remained as to how effective they are in protecting the chronically ill.
“These preliminary results of OCTAVE and the results of our continuing and forthcoming research will be instrumental in helping inform how best to vaccinate patients with chronic conditions and protect them from COVID-19 infection in the future.”
Dr Rob Buckle, Chief Scientist of the Medical Research Council, part of UKRI, which co-funded the trial, said: “Today’s results will be of concern for the subset of people within those who are immunosuppressed for whom the vaccine didn’t trigger a large protective response. We’re funding an extension to the OCTAVE study to give third jabs to this group, which we hope will deliver a much-needed immunity boost, or identify those who could benefit from other interventions. One of the real strengths of the UK’s scientific response to the pandemic has been the way that we’ve assembled teams of experts to lead cutting-edge and responsive studies like this, to inform our vaccine roll-out and government decision-making in real time.”
The OCTAVE (Observational Cohort Trial-T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2) study looks at those with immune-mediated inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ANCA-Associated Vasculitis, inflammatory bowel disease, as well as hepatic disease and renal failure. So far, more than 2,500 patients have been recruited to the trial — making it one of the largest global studies in which detailed immune response is being assessed post-SARS-CoV-2 vaccination.
The data reported in this pre-print include the post-vaccine immune response results from the first 600 patients recruited 4 weeks post second dose.
As the study progresses, around 3000 people will be recruited. Participants in the study have all received either COVID-19 mRNA Vaccine BNT162b2 (Pfizer/BioNTech) or ChAdOx1 Vaccine (AstraZeneca) as part of the National COVID19 vaccination programme.